Sequentify, emanating from the Weizmann Institute, is a leader in developing targeted Next-Generation Sequencing (NGS) library solutions. We specialize in offering innovative NGS kits to laboratories, enabling them to conduct advanced sequencing in-house with unprecedented ease, speed, and affordability. Our standout InfiniSeq kit streamlines the library construction process to a mere 3.15 hours across four steps, ensuring cost-effectiveness and high accuracy. Furthermore, Sequentify stands at the forefront of sample preparation technology with our patent-pending method that allows for efficient pooling of multiple samples early in the protocol, significantly increasing throughput.

In addition to our physical kits, we provide comprehensive bioinformatics tools, allowing labs to process and analyze data on-premises, ensuring a seamless integration into their existing workflows. Our diverse range of panels, developed for applications in oncology, hematological malignancies, carrier screening, COVID-19, and more, underlines our commitment to advancing diagnostic capabilities.

Tom Fleischer, CEO
[email protected]